M
MycoMedica Life Sciences
Unlocking the healing potential of the fungal genome for people and planet
About MycoMedica Life Sciences
MycoMedica Life Sciences is a Public Benefit Corporation that operates in the biotechnology sector, specifically focusing on the medicinal use of fungi. The company is driven by a mission to leverage the potential of fungi, particularly psilocybin mushrooms, to benefit both people and the planet. The startup's target market includes individuals interested in alternative medicine and organizations in the healthcare sector seeking innovative solutions.
The business model of MycoMedica is centered around research and development of fungi-based products and therapies. The company generates revenue by creating and selling these innovative solutions. The team, led by renowned mycologist, medical researcher, and entrepreneur Paul Stamets, brings a wealth of practical experience and expertise to the table. Stamets' groundbreaking research in the field of fungi has been recognized by numerous awards and is considered a paradigm shift in ecosystem support.
MycoMedica's vision is not just about profit. It is about creating a sustainable future by co-creating and co-nurturing with the help of fungi. The company invites individuals and organizations who understand the intrinsic connection and wisdom of mushrooms to join them in this mission.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Orange, United States
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 70.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Psychedelic Drugs, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Jun 2022 | $60M | $240M | True Ventures · Obvious Ventures · KittyHawk Ventures | ↗ |
Growth signals
Latest recorded traffic for MycoMedica Life Sciences is 190 monthly website visits, down 38.7% over the last three months. MycoMedica Life Sciences's team grew 5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
True Ventures
Obvious Ventures
KittyHawk Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MycoMedica Life Sciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MycoMedica Life Sciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.